Amphastar Pharmaceuticals (AMPH) Total Liabilities (2013 - 2026)

Amphastar Pharmaceuticals' Total Liabilities history runs 14 years deep, the most recent figure standing at $874.8 million for Q1 2026.

• In Q1 2026, Total Liabilities changed 0.03% year-over-year to $874.8 million; the TTM figure through Mar 2026 stood at $874.8 million (changed 0.03% YoY), while the FY2025 annual figure was $840.5 million, down 0.55% from the prior year.
• Total Liabilities was $874.8 million for Q1 2026 at Amphastar Pharmaceuticals, up from $840.5 million in the prior quarter.
• In the past five years, Total Liabilities ranged from a high of $949.5 million in Q3 2023 to a low of $213.3 million in Q4 2022.
• Historically, Total Liabilities has averaged $671.4 million across 5 years, with a median of $840.5 million in 2025.
• The sharpest annual moves came in 2023 and 2024: Total Liabilities jumped 328.61% in 2023, then decreased 13.9% in 2024.
• A 5-year view of Total Liabilities shows it stood at $213.3 million in 2022, then surged by 309.46% to $873.5 million in 2023, then fell by 3.24% to $845.2 million in 2024, then fell by 0.55% to $840.5 million in 2025, then increased by 4.08% to $874.8 million in 2026.
• The last three Total Liabilities figures came in at $874.8 million (Q1 2026), $840.5 million (Q4 2025), and $889.5 million (Q3 2025), per Business Quant data.